Corcept Therapeutics Reports Results for Quarter Ended June 30, 2026

What Happened Corcept Therapeutics Incorporated (CORT) filed an 8-K on July 29, 2026 (Item 7.01) to disclose a press release announcing its financial results for the quarter ended June 30, 2026 and providing a corporate update. The press release is attached to the filing as Exhibit 99.1. The report was signed by Atabak Mokari, Chief Financial Officer, on July 29, 2026.

Key Details

• Filing date: July 29, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Subject: Financial results for the quarter ended June 30, 2026 and a corporate update.
• Attachment: Press release included as Exhibit 99.1 to the 8-K.
• Authorized signer: Atabak Mokari, CFO.

Why It Matters This 8-K notifies investors that Corcept has publicly released its latest quarterly results and corporate update; those details (revenue, earnings, guidance, or operational news) are contained in the attached press release and can influence investor decisions. Retail investors should read the Exhibit 99.1 press release for the specific financial figures and any commentary on growth, outlook, or business developments.